Blue Cross Blue Shield

After a two-year evaluation in advanced non-small cell lung cancers with Allegheny Health Network, the payor will cover the test for its regional members.

The report also identified opportunities to improve adoption through dissemination of evidence supporting the clinical and economic utilization of testing.

When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier.

Blue Shield of California's members will be able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.

The diagnostic will now be a contracted service with Anthem Blue Cross of California and 10 of its affiliated health plans.

The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.

The companies plan to study the current utility and understanding of NGS and precision medicine, and will provide educational programs in underserved areas.

The tests have received coverage decisions from a number of Blue Cross Blue Shield plans this year including ones in California and New Jersey.

The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.

Interpace said that its two thyroid tests are now covered for over 280 million patients nationwide including Medicare, Medicare Advantage, and national and regional health plans.